Stephen T. Worsley

Vice President, Business Development

Stephen Worsley was appointed vice president of business development in November 2013 bringing with him over 25 years in the biotechnology industry with 16 of those in business development. Prior to joining Peregrine he was chief business officer at Centrose Pharmaceuticals and prior to that he held the position of vice president of business development at Intrexon Inc., Zosano Pharma Inc., (a spin out of Johnson & Johnson) and Raven Biotechnologies, Inc. (acquired by MacroGenics).  In addition, he was director of business development at Abgenix (acquired by Amgen), Tripos Drug Discovery, and OHM Technologies (acquired by Carlyle Group). Stephen holds an MBA in finance from the University of Washington and a Bachelor of Science in international economics and finance from the University of Utah.